| abstract |
(57) [Summary]nFormula (I):nEmbedded imagen [Wherein, R 1 Is hydrogen, C 1-6 Alkyl (hydroxy or C 1-4 Optionally substituted by alkoxy), phenyl-C 1-4 Alkyl-, C 1-6 Alkenyl, C 1-6 Alkynyl; R Two Is hydrogen or halogen, NO Two , CN, N Three , CF Three O-, CF Three S-, CF Three SO Two -, CF Three CO-, C 1-6 Alkyl, C 1-6 Alkenyl, C 1-6 Alkynyl, C 1-6 Perfluoroalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl-, C 1-6 Alkyl O-, C 1-6 Alkyl CO-, C 3-6 Cycloalkyl O-, C 3-6 Cycloalkyl CO-, C 3-6 Cycloalkyl-C 1-4 Alkyl O-, C 3-6 Cycloalkyl-C 1-4 Alkyl CO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 Alkyl-, C 1-6 Alkyl S-, C 1-6 Alkyl SO Two −, (C 1-4 Alkyl) Two NSO Two −, (C 1-4 Alkyl) NHSO Two −, (C 1-4 Alkyl) Two NCO-, (C 1-4 Alkyl) NHCO- or CONH Two Or -NR Five R 6 (Where R Five Is hydrogen or C 1-4 Alkyl, R 6 Is hydrogen, C 1-4 Alkyl, formyl, -CO Two C 1-4 Alkyl or -COC 1-4 Alkyl)) or up to three substituents selected from Two The radicals together form a saturated or unsaturated carbocyclic ring optionally containing O or NH; Three Group (s) and R Four The group (s) are each independently hydrogen or C 1-6 Alkyl and / or two R Three Group and / or two R Four When the groups come together C 3-6 Forming a spiroalkyl group, provided that at least one R Three Or R Four Is not hydrogen; X is selected from hydrogen, halogen, cyano, alkyl and alkoxy.] And pharmaceutically acceptable salts and solvates for the treatment of epilepsy, migraine and other disorders And useful for prevention. |